M. Dror Michaelson

28.6k total citations · 8 hit papers
215 papers, 17.1k citations indexed

About

M. Dror Michaelson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, M. Dror Michaelson has authored 215 papers receiving a total of 17.1k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Pulmonary and Respiratory Medicine, 86 papers in Oncology and 65 papers in Cancer Research. Recurrent topics in M. Dror Michaelson's work include Renal cell carcinoma treatment (134 papers), Renal and related cancers (54 papers) and Cancer Genomics and Diagnostics (53 papers). M. Dror Michaelson is often cited by papers focused on Renal cell carcinoma treatment (134 papers), Renal and related cancers (54 papers) and Cancer Genomics and Diagnostics (53 papers). M. Dror Michaelson collaborates with scholars based in United States, Canada and United Kingdom. M. Dror Michaelson's co-authors include Robert J. Motzer, Thomas E. Hutson, Ronald M. Bukowski, Sindy T. Kim, Robert A. Figlin, Charles M. Baum, Piotr Tomczak, Sylvie Négrier, Stéphane Oudard and Isan Chen and has published in prestigious journals such as New England Journal of Medicine, JAMA and Neuron.

In The Last Decade

M. Dror Michaelson

209 papers receiving 16.8k citations

Hit Papers

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell... 2005 2026 2012 2019 2007 2009 2005 2006 2015 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
    2007 4.5k citations Robert J. Motzer, Thomas E. Hutson et al. profile →
  2. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
    2009 1.7k citations Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology profile →
  3. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
    2005 1.3k citations Robert J. Motzer, M. Dror Michaelson et al. Journal of Clinical Oncology profile →
  4. Sunitinib in Patients With Metastatic Renal Cell Carcinoma
    2006 969 citations Robert J. Motzer, Brian I. Rini et al. profile →
  5. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
    2015 688 citations Robert J. Motzer, Thomas E. Hutson et al. profile →
  6. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
    2013 542 citations Robert J. Motzer, Bernard Escudier et al. profile →
  7. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
    2017 507 citations Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology profile →
  8. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience
    2017 252 citations Nicholas J. Giacalone, William U. Shipley et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Dror Michaelson United States 50 12.3k 9.4k 6.1k 6.0k 1.7k 215 17.1k
Cezary Szczylik Poland 54 15.9k 1.3× 14.1k 1.5× 8.1k 1.3× 8.5k 1.4× 1.7k 1.0× 322 23.8k
Sylvie Négrier France 49 13.5k 1.1× 11.0k 1.2× 8.5k 1.4× 6.8k 1.1× 1.8k 1.1× 226 20.8k
Laurence Albigès France 54 10.7k 0.9× 6.5k 0.7× 5.1k 0.8× 4.2k 0.7× 2.1k 1.3× 460 14.4k
Thomas E. Hutson United States 57 17.8k 1.5× 14.8k 1.6× 8.4k 1.4× 9.2k 1.5× 2.7k 1.6× 292 24.8k
Sergio Bracarda Italy 38 7.6k 0.6× 5.8k 0.6× 4.4k 0.7× 3.8k 0.6× 2.1k 1.2× 236 11.6k
Tim Eisen United Kingdom 45 7.0k 0.6× 7.4k 0.8× 4.4k 0.7× 4.1k 0.7× 875 0.5× 145 12.8k
Christine Chevreau France 54 10.2k 0.8× 6.3k 0.7× 6.2k 1.0× 3.8k 0.6× 2.7k 1.6× 310 15.6k
Christian Kollmannsberger Canada 63 8.7k 0.7× 5.5k 0.6× 4.8k 0.8× 3.4k 0.6× 4.2k 2.5× 387 14.0k
Charles M. Baum United States 35 8.2k 0.7× 5.9k 0.6× 4.7k 0.8× 3.4k 0.6× 1.4k 0.9× 71 12.8k
Gary R. Hudes United States 40 6.8k 0.6× 6.1k 0.7× 3.5k 0.6× 3.6k 0.6× 1.2k 0.7× 102 10.7k

Countries citing papers authored by M. Dror Michaelson

Since Specialization
Citations

This map shows the geographic impact of M. Dror Michaelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Dror Michaelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Dror Michaelson more than expected).

Fields of papers citing papers by M. Dror Michaelson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Dror Michaelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Dror Michaelson. The network helps show where M. Dror Michaelson may publish in the future.

Co-authorship network of co-authors of M. Dror Michaelson

This figure shows the co-authorship network connecting the top 25 collaborators of M. Dror Michaelson. A scholar is included among the top collaborators of M. Dror Michaelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Dror Michaelson. M. Dror Michaelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jonasch, Eric, Todd M. Bauer, Kyriakos P. Papadopoulos, et al.. (2023). Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. European Journal of Cancer. 196. 113434–113434. 13 indexed citations
2.
McGregor, Bradley A., Guru Sonpavde, Lucia Kwak, et al.. (2023). The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Annals of Oncology. 35(1). 91–97. 51 indexed citations
3.
Choueiri, Toni K., Todd M. Bauer, Jaime R. Merchan, et al.. (2023). LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC). Annals of Oncology. 34. S1328–S1329. 9 indexed citations
4.
McKay, Rana R., Dominick Bossé, Kathryn P. Gray, et al.. (2018). Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clinical Cancer Research. 24(17). 4081–4088. 26 indexed citations
5.
Giacalone, Nicholas J., William U. Shipley, R.H. Clayman, et al.. (2017). Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. European Urology. 71(6). 952–960. 252 indexed citations breakdown →
6.
Choueiri, Toni K., Susan Halabi, Ben L. Sanford, et al.. (2017). Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology. 35(6). 591–597. 507 indexed citations breakdown →
7.
8.
Rini, Brian I., Thibault De La Motte Rouge, Andrea Harzstark, et al.. (2013). Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib. Clinical Genitourinary Cancer. 11(2). 107–114. 36 indexed citations
9.
Tannir, Nizar M., Christian Kollmannsberger, Marc S. Ernstoff, et al.. (2011). Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer. 47(18). 2706–2714. 24 indexed citations
10.
Zama, Ivan, Thomas E. Hutson, Paul Elson, et al.. (2010). Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 116(23). 5400–5406. 108 indexed citations
11.
Motzer, Robert J., Thomas E. Hutson, Piotr Tomczak, et al.. (2009). Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(22). 3584–3590. 1711 indexed citations breakdown →
12.
Michaelson, M. Dror, Meredith M. Regan, William Oh, et al.. (2009). Phase II study of sunitinib in men with advanced prostate cancer. Annals of Oncology. 20(5). 913–920. 123 indexed citations
13.
Szczylik, Cezary, Stéphane Oudard, Robert A. Figlin, et al.. (2009). 246 OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC). European Urology Supplements. 8(4). 182–182. 9 indexed citations
14.
Rini, Brian I., M. Dror Michaelson, Jonathan E. Rosenberg, et al.. (2008). Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 26(22). 3743–3748. 321 indexed citations
15.
Houk, Brett E., Carlo L. Bello, George D. Demetri, et al.. (2008). Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches. Cancer Research. 68. 5828–5828. 4 indexed citations
16.
Michaelson, M. Dror, Donald S. Kaufman, Hang Lee, et al.. (2007). Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer. Journal of Clinical Oncology. 25(9). 1038–1042. 235 indexed citations
17.
Houk, Brett E., Carlo L. Bello, M. Dror Michaelson, et al.. (2007). 4505 ORAL A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure–response for sunitinib in metastatic renal cell carcinoma (mRCC). European Journal of Cancer Supplements. 5(4). 300–300. 6 indexed citations
18.
Motzer, Robert J., M. Dror Michaelson, Bruce G. Redman, et al.. (2005). Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(1). 16–24. 1304 indexed citations breakdown →
19.
Han, Won Kon, Chin‐Lee Wu, M. Dror Michaelson, et al.. (2005). Human Kidney Injury Molecule-1 Is a Tissue and Urinary Tumor Marker of Renal Cell Carcinoma. Journal of the American Society of Nephrology. 16(4). 1126–1134. 154 indexed citations
20.
Rosenbaum, Daniel M., Pearl S. Rosenbaum, Anita Gupta, et al.. (1997). Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid. Vision Research. 37(24). 3445–3451. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cezary Szczylik Breakdown of academic impact, for papers by Sylvie Négrier Breakdown of academic impact, for papers by Laurence Albigès Breakdown of academic impact, for papers by Thomas E. Hutson Breakdown of academic impact, for papers by Sergio Bracarda Breakdown of academic impact, for papers by Tim Eisen Breakdown of academic impact, for papers by Christine Chevreau Breakdown of academic impact, for papers by Christian Kollmannsberger Breakdown of academic impact, for papers by Charles M. Baum Breakdown of academic impact, for papers by Gary R. Hudes
Rankless by CCL
2026